Norovirus replication, host interactions and vaccine advances

Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis worldwide in all age groups and cause significant disease and economic burden globally. To date, no approved vaccines or antiviral therapies are available to treat or prevent HuNoV illness. Several candidate vaccines are in cl...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Microbiology Vol. 23; no. 6; pp. 385 - 401
Main Authors Prasad, B. V. Venkataram, Atmar, Robert L., Ramani, Sasirekha, Palzkill, Timothy, Song, Yongcheng, Crawford, Sue E., Estes, Mary K.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.06.2025
Nature Publishing Group
Subjects
Online AccessGet full text
ISSN1740-1526
1740-1534
1740-1534
DOI10.1038/s41579-024-01144-9

Cover

More Information
Summary:Human noroviruses (HuNoVs) are the leading cause of acute gastroenteritis worldwide in all age groups and cause significant disease and economic burden globally. To date, no approved vaccines or antiviral therapies are available to treat or prevent HuNoV illness. Several candidate vaccines are in clinical trials, although potential barriers to successful development must be overcome. Recently, significant advances have been made in understanding HuNoV biology owing to breakthroughs in virus cultivation using human intestinal tissue-derived organoid (or enteroid) cultures, advances in structural biology technology combined with epitope mapping and increased metagenomic sequencing. New and unexpected strain-specific differences in pandemic versus non-pandemic virus structures, replication properties and virus–host interactions, including host factors required for susceptibility to infection and pathogenesis, are discussed. In this Review, the authors highlight recent advances in human norovirus biology, including classification, strain-specific differences in cell entry and innate immune responses. They also highlight progress in virus replication, neutralization assays, structural biology and antiviral targets, as well as the status and challenges of vaccine development.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
B.V.V.P., R.L.A., S.R., T.P., Y.S. and M.K.E. researched data for the article. All authors contributed substantially to discussion of the content. B.V.V.P., R.L.A., S.R., T.P. and M.K.E. wrote the article. All authors reviewed and/or edited the manuscript before submission.
Author contributions
ISSN:1740-1526
1740-1534
1740-1534
DOI:10.1038/s41579-024-01144-9